Clinical Trial Update: Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial updating results on adding umeclidinium bromide to fluticasone furoate/vilanterol versus placebo added to fluticasone furoate/vilanterol in COPD; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Breo Ellipta (fluticasone furoate/vilanterol) (fluticasone furoate/vilanterol)
• Incruse Ellipta (umeclidinium bromide) (umeclidinium bromide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-11-25